1234

Thrombosis awareness

Thrombosis awareness is relevant for everyone, and especially for MPN patients. It is provided courtesy of the International Society on Thrombosis and Haemostasis (ISTH).  The ISTH established World Thrombosis Day as 13 October, 'to draw attention to a global health threat that is often overlooked:…
Read more

Final Results: Phase 4 Study of Ruxolitinib for myelofibrosis

A study has just been released in the European Journal of Haematology about the real world impact of ruxolitinib treatment in myelofibrosis patients in Germany. Titled, 'Final Results From a Large, Non-Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine'…
Read more

Ruxolitinib on PBS for polycythemia vera

The MPN AA is delighted to advise that, as of today, 1 September 2025, ruxolitinib is available on the pharmaceutical benefits schedule (PBS) for the treatment of adult patients with polycythemia vera who are resistant to, or intolerant of hydroxycarbamide (hydroxyurea). We have copied and pasted below…
Read more

Polycythemia vera – new way of monitoring disease activity?

A European study has just been released suggesting a new way to monitor polycythemia vera patients' disease activity. Titled 'Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera' it explores the value of using neutrophil-to-lymphocyte…
Read more

MPN Education Symposium in Perth and online

‘What does optimal management of MPNs look like in 2025?’ MPN AA, in partnership with the University of Western Australia School of Biomedical Sciences and Royal Perth Hospital, is proudly presenting an MPN Education Symposium. The symposium will be all day on Saturday 25 October, WA time. It…
Read more

Pegasys update 4 August 2025

Pegasys® is now available - the Irish stock has arrived, however it will not be on the PBS until 1 September 2025 The MPN AA is happy to share the advice that Pegasys® is once again available for Australian patients. BUT it will only be available as a private script during August. For a full…
Read more

Welcome to the MPN Alliance Australia website

MPN stands for Myeloproliferative Neoplasms which are a group of rare chronic blood cancers.

The MPN Alliance Australia, (MPN AA) is run by MPN patients for MPN patients and their families. We all give of our time voluntarily.

MPN patient quality of life is central to everything we do. MPN Alliance Australia aims for these pages to assist patients and families to find support and relevant up to date information related to myeloproliferative neoplasms. This site acts as a portal to comprehensive evidence-based disease information.

We also provide external links to disease-specific articles and other information from Australian and international researchers and clinicians, and MPN organisations.

MPN Alliance Australia welcomes your feedback as we aim to support you as best we can. Please send us a message if you would like to share ideas with us to improve our site.

Share to:
Translate »